<p>在今天發佈的一份報告中，Stifel Nicolaus 的 Paul Matteis 對 Neurocrine 維持了買入評級，目標價為 188.00 美元。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>Matteis 關注醫療保健行業，重點關注如 Xenon、Vertex Pharmaceuticals 和 Ionis Pharmaceuticals 等股票。根據 TipRanks，Matteis 推薦股票的平均回報率為 14.4%，成功率為 50.51%。</p>
<p>除了 Stifel Nicolaus，Neurocrine 還在今天的報告中獲得了 Canaccord Genuity 的 Sumant Kulkarni 的買入評級。然而，在同一天，摩根士丹利對 Neurocrine（NASDAQ: NBIX）重申了持有評級。</p>

神經分泌生物科學

<p>在最近的一份報告中，Stifel Nicolaus 分析師 Paul Matteis 對 Neurocrine (NBIX) 維持了買入評級，目標價為 188.00 美元。Matteis 的平均回報率為 14.4%，成功率為 50.51%，他還覆蓋其他醫療保健股票。此外，Canaccord Genuity 的 Sumant Kulkarni 也對 Neurocrine 發佈了買入評級，而摩根士丹利在同一天重申了持有評級</p>

<p>In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurocrine, with a price target of $188.00.</p>
<div class="lb-trans"><p>在今天發佈的一份報告中，Stifel Nicolaus 的 Paul Matteis 對 Neurocrine 維持了買入評級，目標價為 188.00 美元。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>Matteis covers the Healthcare sector, focusing on stocks such as Xenon, Vertex Pharmaceuticals, and Ionis Pharmaceuticals. According to TipRanks, Matteis has an average return of 14.4% and a 50.51% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Matteis 關注醫療保健行業，重點關注如 Xenon、Vertex Pharmaceuticals 和 Ionis Pharmaceuticals 等股票。根據 TipRanks，Matteis 推薦股票的平均回報率為 14.4%，成功率為 50.51%。</p>
</div><p>In addition to Stifel Nicolaus, Neurocrine also received a Buy from Canaccord Genuity’s Sumant Kulkarni in a report issued today. However, on the same day, Morgan Stanley reiterated a Hold rating on Neurocrine (NASDAQ: NBIX).</p>
<div class="lb-trans"><p>除了 Stifel Nicolaus，Neurocrine 還在今天的報告中獲得了 Canaccord Genuity 的 Sumant Kulkarni 的買入評級。然而，在同一天，摩根士丹利對 Neurocrine（NASDAQ: NBIX）重申了持有評級。</p>
</div>

Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus

Tip Ranks

Stifel Financial

Xenon制藥

福泰制藥

Ionis制藥

摩根士丹利

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

神經分泌生物科學（NBIX）獲得 Stifel Nicolaus 的買入評級